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Interactions between lipid-free apolipoprotein-AI
and a lipopeptide incorporating the RGDS
cell adhesion motif
V. Castelletto,*†a I. W. Hamley,a M. Rezab and J. Ruokolainenb
The interaction of a designed bioactive lipopeptide C16-GGGRGDS, comprising a hexadecyl lipid chain
attached to a functional heptapeptide, with the lipid-free apoliprotein, Apo-AI, is examined. This apolipo-
protein is a major component of high density lipoprotein and it is involved in lipid metabolism and may
serve as a biomarker for cardiovascular disease and Alzheimers’ disease. We ﬁnd via isothermal titration
calorimetry that binding between the lipopeptide and Apo-AI occurs up to a saturation condition, just
above equimolar for a 10.7 μM concentration of Apo-AI. A similar value is obtained from circular dichroism
spectroscopy, which probes the reduction in α-helical secondary structure of Apo-AI upon addition of
C16-GGGRGDS. Electron microscopy images show a persistence of ﬁbrillar structures due to self-assem-
bly of C16-GGGRGDS in mixtures with Apo-AI above the saturation binding condition. A small fraction of
spheroidal or possibly “nanodisc” structures was observed. Small-angle X-ray scattering (SAXS) data for
Apo-AI can be ﬁtted using a published crystal structure of the Apo-AI dimer. The SAXS data for the lipo-
peptide/Apo-AI mixtures above the saturation binding conditions can be ﬁtted to the contribution from
ﬁbrillar structures coexisting with ﬂat discs corresponding to Apo-AI/lipopeptide aggregates.
Introduction
Apolipoproteins are proteins that bind lipids, and are involved
in lipid transport in vivo. There are six classes of apolipo-
protein with diﬀerent structures and biological activities. The
apoliprotein A family is a major component of high density
lipoprotein (HDL). HDL removes fat and cholesterol from cells
and therefore there is significant research interest in the inter-
action of Apo-A apolipoproteins with lipids due to biomedical
relevance, in particular to cardiovascular disease. Among this
class, Apo-AI is the major component of HDL, comprising 70%
of total protein.1 Polymorphism in the gene associated with
Apo-AI has been associated with early onset Alzheimer’s
disease.2
The structure of Apo-AI comprises two domains – the N
terminal (residue 1–186) domain comprises a four-helix
bundle of amphipathic α-helices that result from 11- and
12-residue repeats, whilst the C terminal domain comprises
two further helices, when bound to lipid although less ordered
in the absence of lipid.3–5 Apolipoproteins such as Apo-AI may
adopt a necklace-like structure6 (Fig. 1) and these are able to
wrap around bundles of lipid molecules to form so-called
“nanodiscs”.7,8
The interaction of Apo-AI with various lipids has been the
subject of several studies which indicate that binding between
the apolipoprotein and lipids leads to enhanced α-helix
content.9–11 The binding is believed to be achieved via the
C-terminal α-helices in Apo-AI5,10 which insert into lipid mem-
branes. There is a concomitant increase in α-helical content in
the C terminal domain along with a second step conformation-
al transition in the N terminal helix bundle exposing the
helices to lipid.12 Binding leads to the formation of HDL-like
Fig. 1 Structure of (a) Apo-AI (pdb ﬁle 3R2P,23), (b) Lipopeptide C16-
GGGRGDS.
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aggregates including nascent discoidal particles and circulat-
ing spherical particles.12–14
Here, we investigate for the first time to our knowledge, the
interaction of Apo-AI with a designed lipopeptide. We selected
the lipopeptide C16-GGGRGDS (G: Glycine, R: Arginine, D:
Aspartic Acid and S: Serine) because firstly it contains a bio-
active cell adhesion motif (RGDS) which has been exploited by
us in applications in cell culture supports for tissue engineer-
ing.15,16 Similar lipopeptides have been used by others in
materials for tissue engineering and other cell-based thera-
peutic materials.17,18 Second, its self-assembly has been exten-
sively characterized by ourselves19 and that of similar peptide
amphiphiles has been extensively examined by others.20
Experimental
Materials
Apolipoprotein A-I (Apo-AI), a high density lipoprotein
extracted from human plasma, was purchased from Calbio-
chem (US) and received as a stock solution containing 53.6 μM
Apo-AI in 10 mM NH4HCO3 (pH 7.4). The Apo-I molecular
weight (Mw) is 28 kDa. Lipopeptide C16-GGGRGDS was custom
synthesized by CS Bio (Menlo Park, USA) as a TFA salt. The
purity was 95.46% (by analytical HPLC in a TFA water/acetonitrile
gradient). MW was obtained by electrospray-mass spectrometry.
Mw,Found = 842.99 andMw,Expected = 842.40.
Sample preparation
53.6 μM Apo-AI stock solution was diluted in 10 mM Tris,
0.1 mM NaCl (pH 7.4), while aqueous C16-GGGRGDS solutions
were prepared at pH 8, by titrating 0.1 M NaOH. Binary
samples were made by mixing weighed solutions of Apo-AI
and C16-GGGRGDS at diﬀerent molar ratios Mr = [C16-
GGGRGDS]/[Apo-AI].
Circular dichroism (CD)
Spectra were recorded using a Chirascan spectropolarimeter
(Applied Photophysics, UK). The sample was placed in a cover
slip cuvette (0.01 cm thick). Spectra are presented with absor-
bance A < 2 at any measured point with a 0.5 nm step, 1 nm
bandwidth, and 1 second collection time per step at 20 °C.
The post-acquisition smoothing tool from Chirascan software
was used to remove random noise elements from the averaged
spectra. A residual plot was generated for each curve in order
to verify whether or not the spectrum had been distorted
during the smoothing process. The CD signal from the water
was subtracted from the CD data of the peptide solutions. The
spectra were collected as ellipticity θ as a function of wave-
length and converted to mean residue molar ellipticity [θ] =
θ/(l10c) using the sample molar concentration c = 243 × c1 + 7 ×
c2 (c1: molar concentration of Apo-AI, 243: number of residues
on Apo-AI, c2: molar concentration of C16-GGGRGDS, 7:
number of residues on C16-GGGRGDS).
Small-angle X-ray scattering (SAXS)
Experiments were performed on beamline BM29 at the ESRF
(Grenoble, France). A few microlitres of samples were injected
via an automated sample exchanger at a slow and very reprodu-
cible flux into a quartz capillary (1.8 mm internal diameter),
which was then placed in front of the X-ray beam. The quartz
capillary was enclosed in a vacuum chamber, in order to avoid
parasitic scattering. After the sample was injected in the capil-
lary and reached the X-ray beam, the flow was stopped during
the SAXS data acquisition. The sample was thermostated
throughout its entire travel from the injector to the quartz
capillary. SAXS experiments were performed at 20 °C. The q =
4πsinθ/λ range was set to 0.04–4 nm−1, with λ = 0.1 nm (12
keV). The images were captured using a PILATUS 1M detector.
Data processing (background subtraction, radial averaging)
was performed using dedicated beamline software ISPYB.
SAXS theory
The SAXS data for the 10 μM Apo-AI (Mr = 0) was modelled
using the software Crysol (Version 2.8 ©ATSAS team
1995–2011).21,22 Crysol evaluates the solution scattering from
macromolecules with known atomic structure. In this work, we
used the atomic coordinates for the structure of C Terminal
Truncated Human Apolipoprotein A-I listed in the Protein
Databank File pdb file 3R2P.23 The crystal structure is dis-
played in Fig. 1a. SAXS data for samples with Mr = 2.2–14.9 was
modelled according to a co-existence of flat cylinders, with dia-
meter D and length L, with bilayer tapes described as Gaussian
bilayers interacting through the Caillé structure factor for
multi-layer systems. The details of the model used to describe
the bilayers are provided elsewhere.19,24–26 The model assumes
an electron density profile comprising one Gaussian function
for each headgroup on either side of the bilayer electron
density (ρH) profile, and one Gaussian function for the chains
in the core of the bilayer electron density (ρC) profile. The posi-
tion of the Gaussian peaks is at zH and zC for ρH and ρC
respectively. The model assumes a standard deviation σH and
σC for zH and zC respectively, while the bilayer is centred at z =
zC = 0. We used a Gaussian distribution of zH, with associated
degree of polydispersity ΔZH. The background was taken to be
a constant C0. The fitting parameters of the model are zH,
ρH, σH, ρC, σC and C0. The modified Caillé theory appropriate
for lamellar systems corresponds to a multilayer structure
influenced by thermal fluctuations. It is described by the total
number of layers N, the layer spacing d and the Caillé para-
meter η.25,26
Cryo-transmission electron microscopy (cryo-TEM)
Experiments were carried out using a field emission cryo-elec-
tron microscope (JEOL JEM-3200FSC) operating at 200 kV.
Images were taken using bright-field mode and zero loss
energy filtering (omega type) with a slit with 20 eV. Micro-
graphs were recorded using a Gatan Ultrascan 4000 CCD
camera. The specimen temperature was maintained at −187 °C
during the imaging. Vitrified specimens were prepared using
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an automated FEI Vitrobot device using Quantifoil 3.5/1 holey
carbon copper grids with 3.5 μm hole sizes. Grids were
cleaned using a Gatan Solarus 9500 plasma cleaner just prior
to use and then transferred into an environmental chamber of
an FEI Vitrobot at room temperature and 100% humidity.
Thereafter, 3 μl of sample solution at 2 wt% concentration was
applied on the grid, blotted once for 1 second and then vitri-
fied in a 1/1 mixture of liquid ethane and propane at −180 °C.
Grids with vitrified sample solutions were maintained in a
liquid nitrogen atmosphere and then cryo-transferred into the
microscope.
Transmission electron microscopy (TEM)
TEM imaging was performed using a Philips CM20 TEM
microscope operated at 200 kV. Droplets of solutions were
placed on Cu grids coated with a carbon film (Agar Scientific,
UK), stained with 1 wt% uranyl acetate, and air-dried.
Isothermal titration calorimetry (ITC)
ITC experiments were carried out using an
iTC200 microcalorimeter. The Apo-AI stock solution (53.6 μM
Apo-AI diluted in 10 mM NH4HCO3, pH 7.4) was dissolved to
give a 10.7 μM solution of Apo-AI using 10 mM Tris, 0.1 mM
NaCl, pH 7.4. The working cell was filled with 200 μL of the
10.7 μM Apo-AI solution and the reference cell was filled with
deionized water. The titrant syringe was filled with a solution
of 1.54 mM C16-GGGRGDS (dissolved in the same buﬀer used
for the Apo-AI solution in the working cell). The ITC experi-
ment was programmed to run 18 injections of 2 μL volume of
the titrant solution (1.54 mM C16-GGGRGDS) into the working
cell (10.4 μM of Apo-AI) with 180 s lag between each injection
to ensure return to the baseline. The syringe was stirred
throughout the experiment at 750 rpm and the working cell
was set at 25 °C. The data was analysed using Origin 7 (Micro-
Cal) by fitting the curve using the one set of sites model.
Results
To first probe the possible interactions between Apo-AI and
C16-GGGRGDS (Fig. 1 shows, respectively the structure of Apo-
AI from X-ray crystallography and a molecular model of the PA)
we employed isothermal titration calorimetry (ITC), a well-
known technique to enable investigation of the molecular
interactions of biological samples, in this case a protein-
lipopeptide interaction. The experiment was designed to
inject 1.54 mM C16-GGGRGDS into 53.6 μM Apo-AI, i.e.
C16-GGGRGDS is the ligand and Apo-AI is the receptor. The
relatively low Apo-AI concentration selected for ITC reduces
the total number of binding sites to ensure saturation of C16-
GGGRGDS binding to Apo-AI is reached. The ITC profile for
the titration of C16-GGGRGDS into Apo-AI (Fig. 2a) exhibits a
series of positive peaks, indicating an endothermic reaction.
The integration and normalization of the endothermic peaks
produced a sigmoidal curve relative to the moles of ligand
added, which was then appropriately fitted to a one set of sites
model. The one set of sites model was used for the peptide/
lipopetide system as it is assumed that each binding site has
the same binding aﬃnity. A binding constant K = (3.21 ± 1.7) ×
106 M−1 was determined from the fitting parameters (Fig. 2b).
Other parameters including the number of binding sites N =
(0.59 ± 0.04), enthalpy ΔH = (6.6 ± 0.6) kcal mol−1 and entropy
ΔS = 0.05 Kcal mol−1 °C−1 were also obtained from the fit.
Fig. 2b shows that the system reaches saturation at Mr = 1.2,
because only heat of dilution is observed for Mr > 1.2. ΔH
reflects the strength of the ligand/target interaction enthalphy
relative to that with solvent, primarily due to hydrogen bond
formation and van der Waals interactions. It is highly unlikely
that an endothermic reaction (ΔH > 0), is dominated by hydro-
gen bonding or van der Waals interactions. The isotherm
corresponds to a favourable change in entropy (−TΔS < 0).
Therefore it is possible that Apo-AI/C16-GGGRGDS binding is
driven by hydrophobic interactions. The ITC signal is a result
of many interactions – not just the binding process of Apo-AI
to the lipopeptide but also potential protein conformational
changes upon dilution, lipopeptide/lipopeptide and hydration
eﬀects. However, an unfavourable ΔH associated with an
endothermic process is possibly due to conformational con-
straints of the Apo-AI.27
To our knowledge, there are no prior reports on binding of
Apo-AI to lipopeptides. ITC experiments have been mostly per-
formed to study the binding of lipids to Apo-AI. Although
these experiments show that lipids bind to Apo-AI at room
temperature through an exothermic reaction,10,28–30 one report
shows an endothermic reaction for the titration of Apo-AI into
Fig. 2 (a) Heat release as a function of time and (b) energy released as
a function of the molar ratio for Apo-I titrated with C16-GGGRGDS.
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1-palmitoyl,2-oleoyl phosphatidylcholine/sphingomyelin small
unilamellar vesicles at 37 °C.29
Having determined Mr = 1.2 as the saturation limit for Apo-
AI/C16-GGGRGDS binding at 10.7 μM protein (Fig. 2), further
studies were performed for a fixed concentration of 10.7 μM
Apo-AI, to allow for comparison with results from ITC
experiments.
The influence of interactions between Apo-AI and the lipo-
peptide C16-GGGRGDS on the secondary structure of the lipo-
peptide were examined by CD spectroscopy. CD spectra for
mixtures with Mr = 2.2–14.4 are shown in Fig. 3a. Fig. 3b
shows the dependence with Mr of the ellipticity at the minima
at 209 and 221 nm. Again, saturation is observed above equi-
molar conditions. The results in Fig. 3 show that the amount
of alpha-helix secondary structure decreases upon increasing
Mr. Previous studies have shown that human Apo-AI has high
α-helical content, values between 43%–68% having been
reported,1,9–11,31 in good agreement with the CD for pure Apo-
AI in Fig. 3a. To further evaluate whether interactions between
Apo-AI and C16-GGGRGDS modify the secondary structure, we
compared measured CD spectrum with those calculated by the
addition of the spectra for the individual components. Fig. 4 is
a representative comparison showing a large diﬀerence
between the measured and calculated spectra for one of the
mixtures studied (Mr = 4.5). In this case, the calculated spectra
corresponds to the one-to-one addition of the CD spectrum
measured for 10.7 μM Apo-AI to the CD measured for 48 μM
C16-GGGRGDS (Mr = 48/10.7 = 4.5). The calculated CD spectra
for Mr = 4.5 (Fig. 4) presents a maxima at 193 nm and a
smaller minimum at 225 nm. This spectra is similar to that
reported by us for C16-KTTKS
32 and 154 μM C16-GGGRGDS.19
Our interpretation for the features in the calculated CD spectra
for Mr = 4.5 (Fig. 4) is that they result from red-shifted β-sheet
peaks associated with the lipopeptide fibrils,33 the expected
maximum for this structure being around 195–200 nm and the
minimum being near 216 nm. In contrast, the CD spectra
measured for Mr = 4.5 (Fig. 3–4) is dominated by an α-helical
structure. Fig. 3 and Fig. 4 together indicate that there are
interactions between Apo-AI and C16-GGGRGDS which modify
the secondary structure of each component, specifically there
appears to be a decrease in α-helix content of Apo-AI and a
reduction of β-sheet content of C16-GGGRGDS.
According to the results from CD, the α-helical content of
Apo-AI progressively reduces upon addition of C16-GGGRGDS.
In this way, the eﬀect of lipopeptide titration into the Apo-AI
solution is opposite to the interaction of Apo-AI with various
lipids, in which case binding between the apolipoprotein and
lipids leads to enhanced α-helix content.9–11 However, the
results from CD are in good agreement with ITC (Fig. 2),
because it is possible that Apo-AI forms entropically favoured
structures (such as aggregates) that might lead to the
endothermic reaction measured by ITC experiments.
Cryo-TEM was used to image self-assembled structures in
mixtures of Apo-AI and C16-GGGRGDS above the saturation
condition (Mr > 1). Fig. 5 shows cryo-TEM images measured
for samples with 10.4 μM of Apo-AI and Mr = 2.2, 4.4 and 14.4.
For the sample with Mr = 2.2, thin fibrils can be seen (Fig. 5a)
with a diameter of approximately 10 nm. The fibrils are highly
extended, with lengths up to tens of microns. Upon increasing
the content of C16-GGGRGDS in the solutions, the fibrils
become more twisted as evident in Fig. 5b for Mr = 4.4. Of par-
ticular note, cryo-TEM shows a co-existence of fibrils and
spheroidal aggregates for Mr = 2.2–14.4 (Fig. 5). The average
Fig. 3 (a) CD for Apo-AI/C16-GGGRGDS mixtures measured as a func-
tion of Mr, (b) Dependence on Mr of the CD minima at 209 nm and
221 nm measured in (a).
Fig. 4 (- - -) Experimental and (–––) calculated CD data for Mr = 4.5.
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size of these aggregates was (17.8 ± 4.2) nm, and did not show
a particular dependence with Mr.
The aggregates shown in Fig. 5a–b have similar sizes to the
13 nm and ∼(11.1–13) nm diameter nanodiscs formed through
complexation of Apo-E with dipalmitoylphosphatidylcholine34
and Human Apo-AI with dimyristoylphosphatidylcholine
respectively.7,34 Therefore, it is likely that the aggregates dis-
played in Fig. 5a–c arise from the complexation of the Apo-AI
with C16-GGGRGDS to form nanodiscs. This was further
probed by SAXS (vide infra).
TEM experiments were performed for control solutions
of C16-GGGRGDS. The images displayed in Fig. 6 are for
the lipopeptide solutions, with the same concentrations
used to prepare solutions with Mr = 2.2, 4.4 and 14.4. Extended
fibrils can be observed for all three concentrations, with-
out amorphous aggregates in contrast to the mixtures with
Apo-AI (Fig. 5). The formation of fibres is consistent with
the low critical aggregation concentration for C16-GGGRGDS,
determined to be ∼59 μM (in water).19 Control experi-
ments with Apo-AI only revealed no observable structures
in TEM images at 10.7 μM concentration. It is evident that
the irregular circular aggregates observed in Fig. 5 originate
from the peptide/protein binding, since they are absent in
Fig. 6.
Fig. 5 Cryo-TEM images measured for samples with 10.4 μM of Apo-AI
and Mr = (a) 2.2, (b) 4.4 and (c) 14.4. The insets in (a) and (c) show details
of the aggregates observed for Mr = 2.2 and 14.4 respectively. Fig. 6 TEM images measured for (a) 24, (b) 47 and (c) 154 μM C16-
GGGRGDS. (a), (b) and (c) are the control peptide solutions for the
mixture samples with Mr = 2.2, 4.4 and 14.4 respectively.
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Consequently, the circular objects measured in Fig. 5 might
be closely related to the nanodisc structures observed in pre-
vious lipid/Apo-AI binding studies.7,8
Electron microscopy imaging was complemented with SAXS
experiments. The SAXS curves measured for 10 μM Apo-AI and
Apo-AI/C16-GGGRGDS mixtures above the saturation condition
(Mr > 1) are displayed in Fig. 7. The resulting intensity profiles
provide information on sample-averaged solution nano-
structures, via analysis of the form factor. The form factor
models are described in the Experimental section.
The form factor of Apo-AI (Fig. 6a) was computed from
the published crystal structure as described in the SAXS
Theory section and displayed in Fig. 1a. It agrees very well
with the data. It has been shown that the Apo-AI is not
monomeric for concentrations higher than 0.1 μM.35 The
crystallographic structure used to fit the experimental data
corresponds to dimers of the C-terminal truncated apolipo-
protein.23 Indeed, attempts to model the observed SAXS data
using published crystal structures for several monomeric
forms of Apo-AI6,36 were not successful. The presence of
other oligomeric structures in the sample, as reported on the
basis of analytical ultracentriguation experiments,35 is highly
probable, but a dimer model proved suﬃcient to fit the SAXS
data.
Apparently, the incomplete loop structure of the Apo-AI
dimer shown in Fig. 1a is, in the main, not able to wrap
around the lipopeptide molecules to produce regular nano-
discs. However, cryo-TEM results show a few “nanodisc” struc-
tures in equilibrium with peptide nanofibres, suggesting that
there is a dynamic competition between lipopeptide self-
assembly and lipopeptide binding to Apo-AI.
Therefore, the SAXS data for Mr = 2.2–14.9 was modelled
as a co-existence of flat cylinders with nanotape-like struc-
tures, which accounts for the mixture of extended fibrils and
disk-like objects imaged/revealed by cryo-TEM (Fig. 5). The
form factor for flat discs represents the Apo-AI/lipopetide
aggregates, while the nanotape-like structure represents the
C16-GGGRGDS fibrils. The nanotape-like structure can be
described using a lipid-like bilayer form factor in which the
bilayer is represented by three Gaussian functions (one for
the electron-depleted alkyl chain region and two for the head-
groups at the surface of each bilayer) and has been previously
used by us to describe C16-GGGRGDS and related self-assem-
bling peptide amphiphiles (PAs).19 A structure factor for
lamellar systems is used to account for the stacking of the
bilayers within the PA tapes. The details of the form factors
are given in the Experimental section. The SAXS data is dis-
played in Fig. 7b–d, together with the fitted curves using the
corresponding form factors. The parameters obtained from
the SAXS fitting are listed in Table 1.
The diameter of the flat discs used to fit data in Fig. 7b–d
agrees with the size of the circular objects measured from the
cryo-TEM images in Fig. 5. The estimated length of the
extended C16-GGGRGDS molecule is le = 42 Å, calculated by
adding the length of a C16 chain (18 Å) to the total length of
the peptide block (individual residue period of 3.4 Å).37 The
thickness of the bilayer lT ∼ 2zH + 2σH with Gaussian polydis-
persity ΔZH for zH (Table 1), is shorter than two extended lipo-
peptides molecules lT < 2 × le for Mr = 2.2–14.4, indicating that
the C16 chain probably overlaps giving an interdigitated struc-
ture. It can also be noted that according to previous SAXS
studies, pure C16-GGGRGDS nanotapes are present in solution
as a co-existence of two populations with d = 55 and 70 Å.19
Binding of Apo-AI to C16-GGGRGDS resulted in only one popu-
lation of nanotapes with d = 65 Å (Table 1).
Fig. 7 SAXS data (symbols) along with calculated form factor proﬁles
(full lines) according to the models described in the text. (a) Mr = 0,
(b) Mr = 2.2, (c) Mr = 4.5 and (d) Mr = 14.9 (Table 1).
Table 1 Parameters extracted from the ﬁtting of the SAXS data in Fig. 7b–d for samples containing 10 μM Apo-AI and C16-GGGRGDS at diﬀerent
molar ratios Mr
a
Mr D [Å] L [Å] 2lT [Å] 10
4 × ρH [rel. u.] σH [Å] 10
3 × ρC [rel. u.] σC [Å] Co [a. u.]
2.2 106 ± 34 11.8 65 ± 5 1.9 2.5 −2.6 5 6
4.5 108 ± 34 11.8 65 ± 5 1.8 2.5 −2.7 5 4.5
14.9 108 ± 34 11.2 70 ± 5 0.09 5 −1.5 5 0.4
a N = 2, d = 65 Å and η = 0.4 in structure factor used only for Mr = 14.9.
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Conclusions
The original aim of our work was to prepare lipopeptide/apo-
liproprotein nanodiscs, analogous to those reported for lipids
but containing peptide-functionalised lipopeptide molecules
wrapped with the Apo-AI. We have indeed observed a fraction
of nanodiscs above the saturation binding condition, although
these coexist with fibrillar structures from the lipopeptide self-
assembly process.
We have shown that the lipopeptide C16-GGGRGDS binds to
Apo-AI with a saturation-binding type behaviour. The interaction
is endothermic, which indicates that the binding process is
driven by entropic processes which may correspond to changes
in the conformation of the lipopeptide and/or apolipoprotein
substrate. Circular dichroism spectroscopy provides a similar sat-
uration binding concentration by monitoring the reduction in
α-helical content of Apo-AI upon addition of C16-GGGRGDS.
There also seems to be a reduction in the β-sheet structure of
C16-GGGRGDS. In other words, CD indicates conformational
changes of both Apo-AI and lipopeptide. This points to the
origin of the entropically driven process which leads to a loss of
secondary structure as the two molecules interact.
Electron microscopy imaging reveals the presence of a
mixture of fibrils and nanodiscs above the saturation binding
condition. SAXS provided more insight into the nature of the
self-assembly process and binding interaction. First, it con-
firms the findings from TEM of the presence of a mixture of
fibrils and nanodiscs, also providing detailed (internal) struc-
tural parameters for these assemblies. Secondly, and most
importantly, it shows that the Apo-AI itself is present in solu-
tion in the form of multimers, specifically dimers – although
smaller amounts of other species may also be present. The fact
that the Apo-AI was not present in monomeric form may be
one reason why nanodiscs comprising Apo-AI wrapped around
the lipopeptide were not able to assemble as the main mor-
phology. A fibrillar structure was predominant, although some
nanodiscs were seen reflecting the nature of the Apo-AI
monomer/oligomer equilibrium as well as the lipopeptide self-
assembly process and the possible interplay between these two
equilibria in the mixed system.
This work forms part of a continuing eﬀort to examine the
bioactivity of biofunctional lipopeptides and further eﬀorts to
create lipopeptide nanodiscs are ongoing. Our work suggests
that preparing Apo-AI in monomeric form may be critical to
the synthesis of (entirely) nanodisc assemblies resulting from
lipopeptide/apoliprotein complexation.
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